23.84

2.01% 0.47

After Hours: 23.84

Lyell Immunopharma Inc (LYEL)

Overview News Price History Option Chain Financials Discussions Forecast

Lyell Immunopharma Inc stock is traded at $23.84, with a volume of 86,967. It is up +2.01% in the last 24 hours and up +12.19% over the past month. Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.

Previous Close:

$23.37

Open:

$23.02

24h Volume:

86,967

Relative Volume:

0.86

Market Cap:

$556.15M

Revenue:

$36,000

Net Income/Loss:

$-274.45M

P/E Ratio:

-2.0185

EPS:

-11.8105

Net Cash Flow:

$-150.80M

1W Performance:

+4.06%

1M Performance:

+12.19%

6M Performance:

+37.17%

1Y Performance:

+159.81%

1-Day Range:

$23.02

$24.26

1-Week Range:

$22.37

$25.25

52-Week Range:

$7.65

$45.00

Lyell Immunopharma Inc Stock (LYEL) Company Profile

Name

Lyell Immunopharma Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

650 695-0677

Address

201 HASKINS WAY, SOUTH SAN FRANCISCO

Employee

161

Twitter

Next Earnings Date

2026-03-10

Latest SEC Filings

LYEL's Discussions on Twitter

Compare LYEL vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LYEL Lyell Immunopharma Inc	23.84	545.18M	36,000	-274.45M	-150.80M	-11.81
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-10-26	Initiated	Needham	Buy
Mar-09-26	Initiated	Citizens	Mkt Outperform
Dec-09-25	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-30-24	Downgrade	BofA Securities	Buy → Underperform
Jun-27-24	Downgrade	H.C. Wainwright	Buy → Neutral
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Nov-11-22	Downgrade	Goldman	Buy → Neutral
Oct-17-22	Initiated	H.C. Wainwright	Buy
Jul-12-21	Initiated	BofA Securities	Buy
Jul-12-21	Initiated	Goldman	Buy
Jul-12-21	Initiated	JP Morgan	Overweight
Jul-12-21	Initiated	Morgan Stanley	Overweight

View All

Lyell Immunopharma Inc Stock (LYEL) Latest News

Apr 15, 2026

[EFFECT] Lyell Immunopharma, Inc. SEC Filing - Stock Titan

Apr 15, 2026

Apr 14, 2026

Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4%Should You Sell? - MarketBeat

Apr 14, 2026

Apr 11, 2026

This WhiteFiber Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Sahm

Apr 11, 2026

Needham initiates coverage of Lyell Immunopharma (LYEL) with buy recommendation - MSN

Apr 11, 2026

Apr 10, 2026

Needham & Company LLC Begins Coverage on Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat

Apr 10, 2026

LYEL Earnings History & Surprises | EPS & Revenue Results | LYELL IMMUNOPHARMA INC (NASDAQ:LYEL) - ChartMill

Apr 10, 2026

Lyell Immunopharma (NASDAQ:LYEL) Cut to Strong Sell at Zacks Research - Defense World

Apr 10, 2026

Apr 08, 2026

Signal Recap: Will Lyell Immunopharma Inc outperform tech stocksQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn

Apr 08, 2026

Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference - Sahm

Apr 08, 2026

Apr 07, 2026

Lyell Immunopharma to Present at 25th Annual Needham Virtual Healthcare Conference - National Today

Apr 07, 2026

Cancer drug developer Lyell will webcast a management presentation Apr. 14 - Stock Titan

Apr 07, 2026

Apr 06, 2026

Head to Head Analysis: Lyell Immunopharma (NASDAQ:LYEL) & Mangoceuticals (NASDAQ:MGRX) - Defense World

Apr 06, 2026

Apr 03, 2026

Lyell Immunopharma registers 1.95M shares for resale (NASDAQ: LYEL) - Stock Titan

Apr 03, 2026

Apr 01, 2026

Lyell Immunopharma (NASDAQ:LYEL) Trading Up 9.2%Time to Buy? - MarketBeat

Apr 01, 2026

US Stocks Recap: How sensitive is Lyell Immunopharma Inc to inflation2026 Risk Factors & Reliable Entry Point Alerts - baoquankhu1.vn

Apr 01, 2026

Mar 28, 2026

Lyell Immunopharma (NASDAQ:LYEL) Lowered to Sell Rating by Wall Street Zen - MarketBeat

Mar 28, 2026

Mar 23, 2026

LYEL Technical Analysis & Stock Price Forecast - Intellectia AI

Mar 23, 2026

Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet (NASDAQ:LYEL) - Seeking Alpha

Mar 23, 2026

H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com Canada

Mar 23, 2026

Mar 17, 2026

Is Lyell Immunopharma Inc impacted by rising rates2026 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn

Mar 17, 2026

Mar 16, 2026

Lyell Immunopharma (LYEL) grants CFO 140,000 stock options - Stock Titan

Mar 16, 2026

Lyell Immunopharma (LYEL) CFO Shah identified as insider in Form 3 - Stock Titan

Mar 16, 2026